Molecular Subtyping of Gliomas based on the Integration of Survival Outcome-weighted Multi-omics Data
10.11783/j.issn.1002-3674.2024.05.002
- VernacularTitle:基于生存结局加权多组学数据整合的胶质瘤分子分型
- Author:
Congcong JIA
1
;
Gang DU
;
Xin ZHAO
Author Information
1. 山西医科大学卫生统计教研室(030001)
- Keywords:
Outcome-weighted clustering;
Molecular subtype;
Multi-omics integration;
Gliomas
- From:
Chinese Journal of Health Statistics
2024;41(5):644-649
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the survival outcome-weighted method,survClust,and apply it to the multi-omics data of gliomas,to identify molecular subtypes of gliomas with significant molecular heterogeneity and prognostic differences.Methods The multi-omics data from the Chinese Glioma Genome Atlas(CGGA)was used for outcome weighted integrated subtyping using the survClust method,and a Cox proportional risk model was fitted to assess the prognosis of patients with different subtypes.Differentially expressed genes(DEmiRNAs,DEmRNAs,DMGs)between different subtypes were screened,and Gene Ontology(GO)analysis was performed for overlapping genes among DEmiRNAs target genes,DEmRNAs,and DMGs.Finally,we performed immune infiltration analysis between different subtypes.Results The patients with gliomas were divided into high-risk and low-risk groups by using survClust,and the risk of death for patients in the high-risk group was 2.931 times higher than in the low-risk group.The distribution of differential genes was significantly different among different subtypes,and 194 DEmiRNAs,3396 DEmRNAs,and 1230 DMGs were screened.189 overlapping genes were used for GO analysis,and 52 GO terms with statistically significant differences were obtained.In addition,the level of immune infiltration differed statistically between the different subtypes in terms of B cells,CD4+T cells,CD8+T cells,neutrophils,macrophages and myeloid dendritic cells.Conclusion The outcome-weighted integration algorithm survClust can effectively identify subtypes of gliomas with both molecular heterogeneity and significant prognostic differences.At the same time,the potential biomarkers screened based on subtypes will provide a scientific and theoretical basis for individualized treatment of gliomas.
